FDA Panel Backs Gene Therapy for Advanced Melanoma

An FDA advisory committee meeting on Tuesday supported the approval of RP1 (vusolimogene oderparepvec), a novel gene therapy designed for the treatment of advanced melanoma. The committee's recommendation signifies a crucial step forward for the experimental therapy, which targets unresectable or metastatic cutaneous melanoma that has progressed after prior treatment. The therapy, developed by Replimune Group Inc., utilizes a modified herpes simplex virus (HSV) to selectively infect and destroy cancer cells while also stimulating an anti-tumor immune response.

During the meeting, John Carrino, MD, MPH, of Weill Cornell Medicine in New York City, highlighted the presence of a "signal" within the trial data, stating, "There is some signal there and we should follow that signal." This sentiment reflects the committee's cautious optimism regarding RP1's potential efficacy. The therapy's mechanism involves delivering a gene that encodes for granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that enhances the immune system's ability to recognize and attack cancer cells. The oncolytic virus aspect of RP1 is designed to replicate within tumor cells, causing them to lyse and release tumor-associated antigens, further priming the immune system.

Data presented to the committee included results from the pivotal Phase 2b clinical trial, which evaluated RP1 in patients with advanced melanoma. While specific efficacy metrics such as overall response rate (ORR) and duration of response (DoR) were discussed, the committee's focus was on the overall benefit-risk profile. The therapy is administered via intratumoral injection, meaning it is directly injected into the tumor. This localized delivery aims to maximize the therapeutic effect within the tumor microenvironment while minimizing systemic side effects.

The FDA's Pulmonary-Allergy Drugs Advisory Committee, which reviewed the data, ultimately voted in favor of recommending RP1's approval. This recommendation is non-binding, and the final decision rests with the U.S. Food and Drug Administration (FDA) itself, which typically considers the committee's advice. The potential approval of RP1 could offer a new therapeutic option for patients with advanced melanoma, a disease that remains challenging to treat, particularly in its metastatic stages. The development of oncolytic viruses represents a significant area of research in oncology, aiming to harness the power of viruses to combat cancer.